Bionano Genomics (BNGO) Consolidated Net Income (2017 - 2026)

Bionano Genomics has disclosed Consolidated Net Income across 10 years of filings, most recently posting -$8.3 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at -$8.3 million, down 167.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$31.6 million (up 62.45% YoY), and the FY2025 annual result was -$26.4 million, up 76.53% from the prior year.
• Consolidated Net Income came in at -$8.3 million for Q1 2026 at Bionano Genomics, down from -$7.9 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$3.1 million in Q1 2025 to a low of -$112.6 million in Q3 2023.
• The 5-year median for Consolidated Net Income is -$31.4 million (2024), against an average of -$30.1 million.
• Across the five-year window, Consolidated Net Income sank 253.88% in 2023 and surged 90.13% in 2025, its largest moves.
• Bionano Genomics' Consolidated Net Income stood at -$38.7 million in 2022, then retreated by 13.48% to -$43.9 million in 2023, then surged by 53.15% to -$20.6 million in 2024, then jumped by 61.42% to -$7.9 million in 2025, then slipped by 4.66% to -$8.3 million in 2026.
• The last three Consolidated Net Income figures came in at -$8.3 million (Q1 2026), -$7.9 million (Q4 2025), and -$8.5 million (Q3 2025), per Business Quant data.